Pulse Biosciences Inc
Suletud
SektorTervishoid
19.11 -2.95
Ülevaade
Aktsiahinna muutus
24h
Min
18.98
Max
19.17
Sissetulek | 2M -17M |
|---|---|
Müük | 137K 401K |
Aktsiakasum | -0.18 |
Kasumimarginaal | -6,603.409 |
Töötajad | 116 |
EBITDA | -1.4M -19M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +53.14% upside |
Turukapital | -173M 1.4B |
|---|---|
Eelmine avamishind | 22.06 |
Eelmine sulgemishind | 19.11 |
Tehniline skoor
By Trading Central
Kindlus
Very Strong Bearish Evidence
Pulse Biosciences Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Pulse Biosciences Inc Prognoos
Hinnasiht
By TipRanks
53.14% tõus
12 kuu keskmine prognoos
Keskmine 30 USD 53.14%
Kõrge 30 USD
Madal 30 USD
Põhineb 2 Wall Streeti analüütiku instrumendi Pulse Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.